Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals.

So M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C.

Diabetes Care. 2020 Feb 4. pii: dc191731. doi: 10.2337/dc19-1731. [Epub ahead of print]

PMID:
32019856
2.

Hyaluronan deposition in islets may precede and direct the location of islet immune-cell infiltrates.

Bogdani M, Speake C, Dufort MJ, Johnson PY, Larmore MJ, Day AJ, Wight TN, Lernmark Å, Greenbaum CJ.

Diabetologia. 2020 Mar;63(3):549-560. doi: 10.1007/s00125-019-05066-7. Epub 2020 Jan 6.

PMID:
31907557
3.

High residual C-peptide likely contributes to glycemic control in type 1 diabetes.

Rickels MR, Evans-Molina C, Bahnson HT, Ylescupidez A, Nadeau KJ, Hao W, Clements MA, Sherr JL, Pratley RE, Hannon TS, Shah VN, Miller KM, Greenbaum CJ.

J Clin Invest. 2020 Jan 2. pii: 134057. doi: 10.1172/JCI134057. [Epub ahead of print]

4.

Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC.

Mishra R, Åkerlund M, Cousminer DL, Ahlqvist E, Bradfield JP, Chesi A, Hodge KM, Guy VC, Brillon DJ, Pratley RE, Rickels MR, Vella A, Ovalle F, Harris RI, Melander O, Varvel S, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Yderstræde KB, Tuomi T, Voight BF, Schwartz S, Boehm BO, Groop L, Leslie RD, Grant SFA.

Diabetes Care. 2020 Feb;43(2):418-425. doi: 10.2337/dc19-0986. Epub 2019 Dec 16.

PMID:
31843946
5.

Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression.

Wiedeman AE, Muir VS, Rosasco MG, DeBerg HA, Presnell S, Haas B, Dufort MJ, Speake C, Greenbaum CJ, Serti E, Nepom GT, Blahnik G, Kus AM, James EA, Linsley PS, Long SA.

J Clin Invest. 2020 Jan 2;130(1):480-490. doi: 10.1172/JCI126595.

6.

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M.

Diabetes Care. 2020 Jan;43(1):5-12. doi: 10.2337/dc19-0880. Epub 2019 Nov 21.

PMID:
31753960
7.

High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes.

Vaisar T, Kanter JE, Wimberger J, Irwin AD, Gauthier J, Wolfson E, Bahnam V, Wu IH, Shah H, Keenan HA, Greenbaum CJ, King GL, Heinecke JW, Bornfeldt KE.

Diabetes Care. 2020 Jan;43(1):178-186. doi: 10.2337/dc19-0772. Epub 2019 Oct 9.

PMID:
31597668
8.

Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal Study.

Speake C, Bahnson HT, Wesley JD, Perdue N, Friedrich D, Pham MN, Lanxon-Cookson E, Kwok WW, Sehested Hansen B, von Herrath M, Greenbaum CJ.

Front Immunol. 2019 Sep 13;10:2023. doi: 10.3389/fimmu.2019.02023. eCollection 2019.

9.

Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention.

Sims EK, Geyer S, Johnson SB, Libman I, Jacobsen LM, Boulware D, Rafkin LE, Matheson D, Atkinson MA, Rodriguez H, Spall M, Elding Larsson H, Wherrett DK, Greenbaum CJ, Krischer J, DiMeglio LA; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2019 Dec;42(12):2228-2236. doi: 10.2337/dc19-0593. Epub 2019 Sep 26.

PMID:
31558546
10.

In-vivo assessment of T cell kinetics in individuals at risk for type 1 diabetes.

Hao W, Bahnson HT, Speake C, Cerosaletti K, Greenbaum CJ.

Clin Exp Immunol. 2020 Jan;199(1):50-55. doi: 10.1111/cei.13375. Epub 2019 Oct 7.

PMID:
31557315
11.

Discriminative T cell recognition of cross-reactive islet-antigens is associated with HLA-DQ8 transdimer-mediated autoimmune diabetes.

Chow IT, Gates TJ, Papadopoulos GK, Moustakas AK, Kolawole EM, Notturno RJ, McGinty JW, Torres-Chinn N, James EA, Greenbaum C, Nepom GT, Evavold BD, Kwok WW.

Sci Adv. 2019 Aug 21;5(8):eaaw9336. doi: 10.1126/sciadv.aaw9336. eCollection 2019 Aug.

12.

Abnormalities in proinsulin processing in islets from individuals with longstanding T1D.

Sims EK, Syed F, Nyalwidhe J, Bahnson HT, Haataja L, Speake C, Morris MA, Balamurugan AN, Mirmira RG, Nadler J, Mastracci TL, Arvan P, Greenbaum CJ, Evans-Molina C.

Transl Res. 2019 Nov;213:90-99. doi: 10.1016/j.trsl.2019.08.001. Epub 2019 Aug 9.

PMID:
31442418
13.

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586.

14.

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes.

Acevedo-Calado MJ, Pietropaolo SL, Morran MP, Schnell S, Vonberg AD, Verge CF, Gianani R, Becker DJ, Huang S, Greenbaum CJ, Yu L, Davidson HW, Michels AW, Rich SS, Pietropaolo M; Type 1 Diabetes TrialNet Study Group.

Diabetes. 2019 Sep;68(9):1819-1829. doi: 10.2337/db18-1351. Epub 2019 Jun 5.

PMID:
31167877
15.

Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258-264.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C.

Diabetes Care. 2019 May;42(5):e85-e86. doi: 10.2337/dci19-0012. No abstract available.

PMID:
31010952
16.

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.

17.

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.

Habib T, Long SA, Samuels PL, Brahmandam A, Tatum M, Funk A, Hocking AM, Cerosaletti K, Mason MT, Whalen E, Rawlings DJ, Greenbaum C, Buckner JH; Type 1 Diabetes TrialNet Study Group.

Diabetes. 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. Epub 2019 Mar 20.

18.

Erratum. Genetics coming of age in type 1 diabetes. Diabetes Care 2019;42:189-191.

Cerosaletti K, Hao W, Greenbaum CJ.

Diabetes Care. 2019 May;42(5):987. doi: 10.2337/dc19-er05. Epub 2019 Mar 18. No abstract available.

19.

B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ.

JCI Insight. 2019 Feb 21;4(4). pii: 126136. doi: 10.1172/jci.insight.126136. eCollection 2019 Feb 21.

20.

Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.

Dufort MJ, Greenbaum CJ, Speake C, Linsley PS.

JCI Insight. 2019 Feb 21;4(4). pii: 125556. doi: 10.1172/jci.insight.125556. eCollection 2019 Feb 21.

21.

Genetics Coming of Age in Type 1 Diabetes.

Cerolsaletti K, Hao W, Greenbaum CJ.

Diabetes Care. 2019 Feb;42(2):189-191. doi: 10.2337/dci18-0039. No abstract available. Erratum in: Diabetes Care. 2019 May;42(5):987.

PMID:
30665964
22.

Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice.

Greenbaum C, VanBuecken D, Lord S.

Drugs. 2019 Jan;79(1):43-61. doi: 10.1007/s40265-018-1035-y. Review.

23.

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.

Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network.

Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19.

PMID:
30569273
24.

Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group.

Diabetes Care. 2019 Feb;42(2):258-264. doi: 10.2337/dc17-2625. Epub 2018 Dec 10.

25.

DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes.

James EA, Gillette L, Durinovic-Bello I, Speake C, Bondinas GP, Moustakas AK, Greenbaum CJ, Papadopoulos GK, Kwok WW.

J Immunol. 2018 Dec 15;201(12):3524-3533. doi: 10.4049/jimmunol.1800723. Epub 2018 Nov 19.

26.

Analysis of pancreatic beta cell specific CD4+ T cells reveals a predominance of proinsulin specific cells.

Blahnik G, Uchtenhagen H, Chow IT, Speake C, Greenbaum C, Kwok WW, James EA.

Cell Immunol. 2019 Jan;335:68-75. doi: 10.1016/j.cellimm.2018.11.004. Epub 2018 Nov 7.

PMID:
30428974
27.

First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.

Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, Davis A, Hodge KM, Bradfield JP, Zhou K, Guy VC, Åkerlund M, Wod M, Fritsche LG, Vestergaard H, Snyder J, Højlund K, Linneberg A, Käräjämäki A, Brandslund I, Kim CE, Witte D, Sørgjerd EP, Brillon DJ, Pedersen O, Beck-Nielsen H, Grarup N, Pratley RE, Rickels MR, Vella A, Ovalle F, Melander O, Harris RI, Varvel S, Grill VER; Bone Mineral Density in Childhood Study, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Åsvold BO, Yderstræde KB, Pearson ER, Schwartz S, Voight BF, Hansen T, Tuomi T, Boehm BO, Groop L, Leslie RD, Grant SFA.

Diabetes Care. 2018 Nov;41(11):2396-2403. doi: 10.2337/dc18-1032. Epub 2018 Sep 25.

28.

Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes.

Cabrera SM, Engle S, Kaldunski M, Jia S, Geoffrey R, Simpson P, Szabo A, Speake C, Greenbaum CJ; Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Chen YG, Hessner MJ.

Diabetologia. 2018 Nov;61(11):2356-2370. doi: 10.1007/s00125-018-4708-x. Epub 2018 Aug 30.

29.

ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents.

Couper JJ, Haller MJ, Greenbaum CJ, Ziegler AG, Wherrett DK, Knip M, Craig ME.

Pediatr Diabetes. 2018 Oct;19 Suppl 27:20-27. doi: 10.1111/pedi.12734. No abstract available.

PMID:
30051639
30.

Palestinian Adolescents' Prolonged Exposure to Political Violence, Self- Esteem, and Post-Traumatic Stress Symptoms.

Haj-Yahia MM, Greenbaum CW, Lahoud-Shoufany L.

J Interpers Violence. 2018 Jul 1:886260518789144. doi: 10.1177/0886260518789144. [Epub ahead of print]

PMID:
30027784
31.

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.

32.

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ.

Genes Immun. 2019 Apr;20(4):293-307. doi: 10.1038/s41435-018-0032-1. Epub 2018 Jun 21.

33.

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA.

Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16.

34.

Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.

Marre ML, McGinty JW, Chow IT, DeNicola ME, Beck NW, Kent SC, Powers AC, Bottino R, Harlan DM, Greenbaum CJ, Kwok WW, Piganelli JD, James EA.

Diabetes. 2018 Jul;67(7):1356-1368. doi: 10.2337/db17-1166. Epub 2018 Apr 13.

35.

Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.

Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ.

Diabetes Care. 2018 Apr;41(4):653-661. doi: 10.2337/dc17-0806.

36.

Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2018 Apr;41(4):913. doi: 10.2337/dc18-er04a. Epub 2018 Feb 23. No abstract available.

37.

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.

Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ.

JAMA. 2017 Nov 21;318(19):1891-1902. doi: 10.1001/jama.2017.17070.

38.

Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease.

Buckner JH, Greenbaum CJ.

J Immunol. 2017 Nov 1;199(9):3011-3013. doi: 10.4049/jimmunol.1701299. No abstract available.

39.

Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Hao W, Woodwyk A, Beam C, Bahnson HT, Palmer JP, Greenbaum CJ.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4428-4434. doi: 10.1210/jc.2017-01713. Erratum in: J Clin Endocrinol Metab. 2018 Apr 1;103(4):1653.

40.

Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.

Greenbaum C, Lord S, VanBuecken D.

Curr Diab Rep. 2017 Oct 17;17(11):119. doi: 10.1007/s11892-017-0932-x. Review.

PMID:
29039056
41.

Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Dec;60(12):2540. doi: 10.1007/s00125-017-4446-5. No abstract available.

42.

Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Nov;60(11):2139-2147. doi: 10.1007/s00125-017-4384-2. Epub 2017 Aug 2. Review. Erratum in: Diabetologia. 2017 Sep 26;:.

43.

Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.

Schwedhelm K, Thorpe J, Murray SA, Gavin M, Speake C, Greenbaum C, Cerosaletti K, Buckner J, Long SA.

Clin Immunol. 2017 Aug;181:67-74. doi: 10.1016/j.clim.2017.06.004. Epub 2017 Jun 20.

44.

Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes.

Cerosaletti K, Barahmand-Pour-Whitman F, Yang J, DeBerg HA, Dufort MJ, Murray SA, Israelsson E, Speake C, Gersuk VH, Eddy JA, Reijonen H, Greenbaum CJ, Kwok WW, Wambre E, Prlic M, Gottardo R, Nepom GT, Linsley PS.

J Immunol. 2017 Jul 1;199(1):323-335. doi: 10.4049/jimmunol.1700172. Epub 2017 May 31.

45.

Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes.

Yang J, Wen X, Xu H, Torres-Chinn N, Speake C, Greenbaum CJ, Nepom GT, Kwok WW.

J Immunol. 2017 Jul 1;199(1):91-96. doi: 10.4049/jimmunol.1601570. Epub 2017 May 26.

46.

Measurement of Pro-Islet Amyloid Polypeptide (1-48) in Diabetes and Islet Transplants.

Courtade JA, Klimek-Abercrombie AM, Chen YC, Patel N, Lu PYT, Speake C, Orban PC, Najafian B, Meneilly G, Greenbaum CJ, Warnock GL, Panagiotopoulos C, Verchere CB.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2595-2603. doi: 10.1210/jc.2016-2773.

PMID:
28368485
47.

Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home.

Speake C, Whalen E, Gersuk VH, Chaussabel D, Odegard JM, Greenbaum CJ.

Clin Exp Immunol. 2017 May;188(2):226-233. doi: 10.1111/cei.12916. Epub 2017 Mar 2.

48.

Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Hundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH.

Sci Transl Med. 2016 Sep 14;8(356):356ra119. doi: 10.1126/scitranslmed.aad9943.

49.

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.

Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. Epub 2016 Jul 15.

50.

Acute hyperglycemia impairs IL-6 expression in humans.

Spindler MP, Ho AM, Tridgell D, McCulloch-Olson M, Gersuk V, Ni C, Greenbaum C, Sanda S.

Immun Inflamm Dis. 2016 Jan 19;4(1):91-7. doi: 10.1002/iid3.97. eCollection 2016 Mar.

Supplemental Content

Loading ...
Support Center